FDA Approval of Subcutaneous Amivantamab Is Significant Step Forward in NSCLC: Martin Dietrich, MD, PhD | AJMC
FDA Approval of Subcutaneous Amivantamab Is Significant Step F…
1 month ago
ajmc.com
PAPILLON Study - Amivantamab Chemo vs. Chemo as 1L Treatment in EGFR Exon 20 Insertion-Mutated Advanced NSCLC
PAPILLON Study - Amivantamab Chemo vs. Chemo as 1L Treatmen…
854 viewsNov 17, 2023
vumedi.com
Dr Sabari on the FDA Approval of Frontline Amivantamab Plus Chemo in EGFR Exon 20 Insertion NSCLC | OncLive
2:07
Dr Sabari on the FDA Approval of Frontline Amivantamab Plus Che…
Mar 29, 2024
onclive.com
Dr Arnold on the Evaluation of Chemo With Amivantamab or Cetuximab in RAS/BRAF Wild-Type mCRC | OncLive
Dr Arnold on the Evaluation of Chemo With Amivantamab or Cetu…
7 months ago
onclive.com
Amivantamab Accolades Add Up for NSCLC | AJMC
3:48
Amivantamab Accolades Add Up for NSCLC | AJMC
1 month ago
ajmc.com
ESMO 2025 Insights: Amivantamab in Recurrent/Metastatic HNSCC After Progression on Checkpoint Inhibition and Chemo - OrigAMI-4 Study Results
ESMO 2025 Insights: Amivantamab in Recurrent/Metastatic HNSCC Af…
3 months ago
vumedi.com
WCLC 2025 Insights: Subcutaneous Amivantamab Q4 Weeks Lazertinib in 1L EGFR-Mutated Advanced NSCLC - PALOMA-2 Data
WCLC 2025 Insights: Subcutaneous Amivantamab Q4 Weeks Lazertini…
4 months ago
vumedi.com
Dr. Marmarelis on the Efficacy of Lazertinib/Amivantamab Plus Che…
1 week ago
onclive.com
8:58
Subcutaneous Amivantamab vs Intravenous Amivantamab, Both i…
Jun 25, 2024
onclive.com
Dr Pietrantonio on Amivantamab With/Without Chemotherapy in Rig…
1 year ago
onclive.com
Amivantamab in 1L Advanced NSCLC With EGFR exon 20 Inserti…
44 viewsMay 1, 2024
vumedi.com
Treatment Options for EGFRm NSCLC: Amivantamab Lazertinib
129 views11 months ago
vumedi.com
MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant N…
Dec 27, 2023
onclive.com
2021 ASCO Review on EGFR Resistance Strategies in NSCLC: …
275 viewsJul 19, 2021
vumedi.com
Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mu…
Jun 19, 2024
onclive.com
Dr Girard on the Efficacy of First-Line Amivantamab Plus Chemothe…
Oct 21, 2023
onclive.com
21:25
Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Ch…
Oct 31, 2023
onclive.com
13:44
Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Tre…
Nov 30, 2023
onclive.com
1:14
Predictive Biomarkers for Treatment With Amivantamab Plus Lazertini…
Apr 29, 2024
onclive.com
ASCO® 2024 Insights: "CHRYSALIS-2 Trial - Amivantamab Lazertinib i…
79 viewsJun 14, 2024
vumedi.com
Novel Mechanisms Set FDA-Approved Amivantamab-Lazertini…
Aug 30, 2024
ajmc.com
ASCO® 2024 Insights: "PALOMA-2 Study - Subcutaneous Amivantam…
140 viewsJun 11, 2024
vumedi.com
6:53
Amivantamab Lazertinib in EGFR-Mutated Advanced NSCLC: Result…
Nov 14, 2023
targetedonc.com
Dr Joshua Sabari Discusses Amivantamab’s First-Line Approv…
Mar 4, 2024
ajmc.com
Dr Powell on the FDA Approval of Dostarlimab Plus Chemo in Advan…
Sep 4, 2024
onclive.com
1:34
Dr Sabari on the FDA Approval of Amivantamab/Lazertinib in EGFR …
Sep 4, 2024
onclive.com
Dr Leighl on Amivantamab in Advanced NSCLC With MET Exon …
Sep 12, 2023
onclive.com
Dr Hassan on the CHRYSALIS trial of Amivantamab in EGFR Exon 20…
Apr 3, 2023
onclive.com
13:00
Amivantamab Lazertinib Versus Osimertinib as 1L Treatment in EG…
Nov 10, 2023
onclive.com
30:56
7.8K views · 99 reactions | Bad Start To New Treatment ( Amivantamab...
3.5K views1 week ago
FacebookJenny Appleford
See more videos
Static thumbnail place holder